Ntzifa et al., 2021 - Google Patents
DNA methylation analysis in plasma cell-free DNA and paired CTCs of NSCLC patients before and after osimertinib treatmentNtzifa et al., 2021
View HTML- Document ID
- 17142540680438730427
- Author
- Ntzifa A
- Londra D
- Rampias T
- Kotsakis A
- Georgoulias V
- Lianidou E
- Publication year
- Publication venue
- Cancers
External Links
Snippet
Simple Summary Liquid biopsy is a highly useful tool for the management of NSCLC patients and could provide valuable information on early detection of resistance to osimertinib. Epigenetic biomarkers are very promising for the early diagnosis, prognosis …
- 230000007067 DNA methylation 0 title abstract description 82
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
- C12Q1/6886—Hybridisation probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/10—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology
- G06F19/18—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology for functional genomics or proteomics, e.g. genotype-phenotype associations, linkage disequilibrium, population genetics, binding site identification, mutagenesis, genotyping or genome annotation, protein-protein interactions or protein-nucleic acid interactions
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q50/00—Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
- G06Q50/10—Services
- G06Q50/22—Health care, e.g. hospitals; Social work
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Incorvaia et al. | A “Lymphocyte MicroRNA Signature” as predictive biomarker of immunotherapy response and plasma PD-1/PD-L1 expression levels in patients with metastatic renal cell carcinoma: pointing towards epigenetic reprogramming | |
Deng et al. | Long non-coding RNA as potential biomarker for prostate cancer: is it making a difference? | |
Liu et al. | MicroRNA-944 affects cell growth by targeting EPHA7 in non-small cell lung cancer | |
Gasparello et al. | A distinctive microRNA (miRNA) signature in the blood of colorectal cancer (CRC) patients at surgery | |
Tonella et al. | Prognostic and predictive biomarkers in stage III melanoma: Current insights and clinical implications | |
Nobili et al. | Long non-coding RNAs in multiple myeloma | |
Choi et al. | ALDH1A2 is a candidate tumor suppressor gene in ovarian cancer | |
Ntzifa et al. | DNA methylation analysis in plasma cell-free DNA and paired CTCs of NSCLC patients before and after osimertinib treatment | |
Schmidt et al. | A pilot study to non-invasively track PIK3CA mutation in head and neck cancer | |
Azzollini et al. | Constitutive BRCA1 promoter hypermethylation can be a predisposing event in isolated early-onset breast cancer | |
Weng et al. | DNA methylation analysis identifies patterns in progressive glioma grades to predict patient survival | |
Carrasco et al. | Cell-free DNA as a prognostic biomarker for monitoring muscle-invasive bladder cancer | |
Schraa et al. | Cell-free circulating (tumor) DNA before surgery as a prognostic factor in non-metastatic colorectal cancer: a systematic review | |
Jeong et al. | Genome-wide methylation profiling in canine mammary tumor reveals miRNA candidates associated with human breast cancer | |
Kim et al. | Diagnostic value of circulating miR-202 in early-stage breast cancer in South Korea | |
Ishibashi et al. | High frequency of PIK3CA mutations in low-grade serous ovarian carcinomas of Japanese patients | |
Jasmine et al. | Interaction between microsatellite instability (MSI) and tumor DNA methylation in the pathogenesis of colorectal carcinoma | |
Merkerova et al. | Relationship between altered miRNA expression and DNA methylation of the DLK1-DIO3 region in azacitidine-treated patients with myelodysplastic syndromes and acute myeloid leukemia with myelodysplasia-related changes | |
Søgaard Helbo et al. | Hypermethylation of the VTRNA1-3 promoter is associated with poor outcome in lower risk myelodysplastic syndrome patients | |
Kujala et al. | Circulating cell-free DNA reflects the clonal evolution of breast cancer tumors | |
Flores-Chova et al. | Plasma exosomal non-coding RNA profile associated with renal damage reveals potential therapeutic targets in lupus nephritis | |
Romanova et al. | RUNX1/CEBPA mutation in acute myeloid leukemia promotes hypermethylation and indicates for demethylation therapy | |
Garajei et al. | Evaluation of the expression of miR-486-3p, miR-548-3p, miR-561-5p and miR-509-5p in tumor biopsies of patients with oral squamous cell carcinoma | |
Dudea-Simon et al. | Alteration of gene and miRNA expression in cervical intraepithelial neoplasia and cervical cancer | |
Bos et al. | ESR1 methylation measured in cell-free DNA to evaluate endocrine resistance in metastatic breast cancer patients |